Author : Shahanawaz khan from Central University Of Punjab Co -Author : Jamshida. K from Central University Of Punjab
Abstract
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is one of the most important advancements in modern biotechnology, enabling precise and efficient modification of genetic material. Its application in human gene editing offers significant potential for treating genetic disorders, cancer, and other hereditary diseases. However, its use raises complex legal and ethical concerns. A major challenge involves germline gene editing, where genetic changes can be inherited by future generations, creating concerns regarding safety, consent, and unforeseen consequences. Ethical issues such as “designer babies,” social inequality, genetic discrimination, and impacts on human dignity have generated widespread debate. From a legal perspective, the absence of comprehensive regulatory frameworks, liability concerns, intellectual property disputes, and differences in international regulations present significant challenges. The controversial case of CRISPR-edited babies in China highlighted the need for stronger global governance and ethical oversight. This article examines these legal and ethical challenges and emphasizes the need for a balanced regulatory framework that promotes scientific innovation while safeguarding human dignity, public welfare, and future generations.
Keywords:
CRISPR Technology, Human Gene Editing, Biotechnology, Germline Editing, Bioethics, Informed Consent, Regulatory Framework, Genetic Privacy, Designer Babies.
Introduction
The rapid advancement of biotechnology has transformed modern medicine and genetic research. One of the most significant developments is CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), a gene-editing technology that enables precise modification of DNA sequences. It has revolutionized biological research by making gene editing faster, more accurate, and more affordable than earlier methods. CRISPR offers promising applications in treating inherited genetic disorders, combating diseases, and advancing scientific knowledge.The technology has generated considerable interest because of its potential to prevent or treat conditions such as sickle cell anemia, cystic fibrosis, and Huntington’s disease. However, the ability to alter the human genome raises important legal, ethical, and social concerns. Germline editing, which can pass genetic changes to future generations, remains particularly controversial due to risks of unintended consequences, genetic discrimination, social inequality, and the possibility of “designer babies.”Existing legal frameworks often struggle to address issues such as safety, informed consent, liability, intellectual property rights, and international governance. This article examines the legal and ethical challenges of CRISPR-based human gene editing and highlights the need for a comprehensive regulatory framework that promotes responsible innovation while protecting human dignity and future generations.
OVERVIEW OF CRISPR-Cas9 TECHNOLOGY
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, while Cas9 refers to CRISPR-associated protein 9, an enzyme that cuts DNA at specific locations. CRISPR-Cas9 is a gene-editing technology that enables precise changes in the DNA of living organisms, functioning like molecular scissors guided by a navigation system. CRISPR sequences were first observed in 1987 by Japanese scientist Yoshizumi Ishino and his team, though their significance was not then understood. Later, scientists discovered their role in bacterial immunity. The technology was further developed by Jennifer Doudna and Emmanuelle Charpentier, who received the 2020 Nobel Prize in Chemistry.
Genes Modification Using CRISPR
CRISPR-Cas9 can modify genes in several ways after cutting DNA at a specific location. It can remove a defective gene (gene knockout) to prevent harmful effects, such as genes causing hereditary disorders. It can repair faulty genes by replacing defective DNA with healthy sequences, as in sickle cell anemia treatment. CRISPR can also insert new genes to provide desired traits, such as disease resistance in crops. Additionally, it can replace or alter existing genes to improve their function, a method used in advanced therapies, including modifying immune cells to recognize and destroy cancer cells.
Functioning of CRISPR-Cas9
Scientists first identify the specific DNA sequence that requires modification, which is the first step in the gene-editing process. A guide RNA is then created to match the target DNA sequence and direct the editing machinery to the correct location. The guide RNA guides the Cas9 enzyme to the target site in the genome, ensuring accurate recognition of the selected DNA sequence. The Cas9 enzyme then cuts both strands of DNA at the selected site, creating a break that allows genetic modifications to be made. Finally, the cell repairs the DNA break, during which genes can be removed, repaired, inserted, or replaced, resulting in the desired genetic change.
Applications of CRISPR-Cas9
Medical Applications: CRISPR is used to develop treatments for genetic disorders and other diseases. It has significant potential in improving human health through targeted gene therapy. Example: Treatment of sickle cell anemia and certain forms of cancer.Agricultural Applications: The technology helps develop crops with higher yields, improved nutrition, and disease resistance. It contributes to enhancing food security and agricultural productivity. Example: Production of pest-resistant rice and drought-tolerant crops.Scientific Research: Researchers use CRISPR to study gene functions and understand diseases. This enables scientists to investigate genetic mechanisms more effectively. Example: Creating animal models for studying genetic disorders. Environmental Applications: CRISPR can be used to control disease-carrying organisms and protect ecosystems. It offers innovative solutions for addressing environmental and public health challenges. Example: Research on genetically modified mosquitoes to reduce malaria transmission.
LEGAL CHALLENGES OF CRISPR TECHNOLOGY AND HUMAN GENE EDITING
By enabling precise genome editing and providing new avenues for the treatment of hereditary illnesses, CRISPR-Cas9 has completely transformed the field of genetics. Its capacity to change human DNA, however, presents difficult legal questions pertaining to genetic information, autonomy, privacy, reproductive rights, and the interests of future generations. These difficulties highlight the critical need for strong legal frameworks that strike a balance between the advancement of science and the defense of human rights and dignity.
Informed consent
Informed consent is a fundamental principle of medical law and bioethics, requiring individuals to voluntarily agree to a medical procedure after receiving complete information about its risks, benefits, alternatives, and possible consequences. In the context of CRISPR technology, informed consent becomes particularly complex. While adults may consent to somatic gene-editing therapies that affect only their own bodies, germline editing has implications for future generations who cannot provide consent, raising concerns about the legitimacy of making irreversible genetic decisions on behalf of unborn persons. In Samira Kohli v. Dr. Prabha Manchanda (2008), the Supreme Court of India held that a patient has the right to receive adequate information before consenting to medical treatment and that consent obtained without proper disclosure is invalid. This principle is highly relevant to CRISPR-based therapies, where patients must understand not only immediate risks but also potential long-term genetic consequences. Internationally, the case of Henrietta Lacks Case highlighted serious concerns regarding the lack of informed consent, ownership of biological materials, exploitation of patients in research, and the ethical use of genetic information after cells taken from Henrietta Lacks without her knowledge in 1951 became the basis for significant scientific advancements.
Similarly, in Moore v. Regents of the University of California (1990), cells taken from patient John Moore were used to develop commercially valuable medical products without his knowledge, raising important legal questions concerning ,patient consent, the commercial use of biological materials, and ownership rights over genetic resources. These cases continue to shape contemporary debates on CRISPR research, genetic data, biotechnology, and the ethical governance of gene-editing technologies.
Right to Privacy and Genetic Data Protection
Gene-editing procedures require access to highly sensitive genetic information that can reveal an individual’s health status, hereditary conditions, family relationships, and other biological characteristics. The misuse or unauthorized disclosure of such information may result in genetic discrimination, breach of confidentiality, employment discrimination, insurance discrimination, and social stigma. The importance of protecting genetic data was constitutionally recognized in Justice K.S. Puttaswamy v. Union of India (2017), where the Supreme Court held that privacy is a fundamental right under Article 21 of the Constitution. The judgment specifically emphasized informational privacy and the need to safeguard personal data. Since genetic information constitutes one of the most sensitive forms of personal information, it warrants enhanced legal protection. The Puttaswamy decision therefore provides a strong constitutional foundation for regulating genetic databases, DNA repositories, and CRISPR-based gene-editing research to ensure the privacy and dignity of individuals.
Reproductive Autonomy
Reproductive autonomy refers to an individual’s right to make decisions regarding reproduction and family life without undue interference. CRISPR and other gene-editing technologies may enable parents to prevent hereditary diseases or select embryos with preferred characteristics, potentially improving health and well-being. However, such interventions also raise concerns about the extent of parental control over a child’s genetic identity and future autonomy. In Suchita Srivastava v. Chandigarh Administration (2009), the Supreme Court recognized reproductive choice as an integral part of personal liberty protected under Article 21 of the Constitution and emphasized that decisions relating to reproduction primarily belong to the individual concerned. The principles established in this case are highly relevant to CRISPR technology, as genetic interventions increasingly shape reproductive choices and raise important questions concerning individual freedom, parental decision-making, and the rights of future generations.
Intergenerational Justice
Intergenerational justice refers to the responsibility of the present generation to protect the interests and rights of future generations. This principle is particularly significant in the context of germline gene editing, as unlike ordinary medical treatments, its genetic modifications may be inherited indefinitely by future descendants. Any unintended or harmful consequences of such interventions could therefore affect individuals who never consented to them. The concept raises important legal and ethical questions, including whether the present generation has the authority to alter the genetic inheritance of future generations, who should bear liability for unforeseen genetic harms, and how the rights of future persons can be adequately safeguarded.
Owing to these concerns and the uncertainty surrounding long-term effects, many legal scholars advocate that germline gene editing should remain subject to strict regulation until its safety, effectiveness, and long-term implications are fully understood.
Human Enhancement and Designer Babies
CRISPR technology may be used not only for therapeutic purposes but also for enhancement purposes. Human enhancement refers to the use of genetic technologies to improve traits beyond what is considered normal human functioning. Examples include enhanced intelligence, increased strength, improved memory, and superior athletic ability. Such interventions raise concerns regarding equality, fairness, and human dignity.A designer baby is a child whose genetic characteristics are deliberately selected or altered before birth. Potential modifications may include eye colour, height, intelligence, physical appearance, and athletic capabilities. The possibility of designer babies has generated legal concerns regarding discrimination, social inequality, and the revival of eugenic practices.The He Jiankui controversy (2018), in which He Jiankui announced the birth of genetically edited twins in China, demonstrated the dangers of inadequate legal oversight. The incident generated international criticism and highlighted the urgent need for effective regulation of human gene editing.
BIOETHICAL ISSUES OF CRISPR TECHNOLOGY AND HUMAN GENE EDITING
CRISPR-Cas9 has revolutionized biotechnology by enabling precise gene editing, offering immense medical potential while raising critical ethical concerns about human dignity, equality, and future generations.
Human Dignity
Human dignity is a fundamental principle of bioethics that recognizes the inherent worth of every human being. CRISPR technology raises concerns that extensive genetic modification may treat humans as objects of design and manipulation. Critics argue that selecting traits such as intelligence, height, or appearance could reduce respect for human uniqueness, individuality, and autonomy. In such cases, children may be viewed as products of genetic design rather than persons with inherent dignity, creating significant ethical concerns.
Germline Gene Editing
Germline gene editing involves modifying the DNA of embryos, sperm, or egg cells, and unlike somatic editing, these changes can be inherited by future generations. Supporters argue that it can eliminate hereditary diseases and improve human health. However, critics point out that its long-term effects remain uncertain. Major ethical concerns include the inability of future generations to consent, the risk of permanently inherited unintended genetic changes, reduced genetic diversity, and irreversible consequences for future populations. In 2018, He Jiankui announced the birth of genetically edited twin girls, triggering widespread criticism. The incident highlighted the ethical risks of germline editing and the need for strict scientific and regulatory oversight.
Therapeutic Editing and Enhancement Editing
One of the major ethical debates surrounding CRISPR technology is the distinction between therapeutic and enhancement gene editing. Therapeutic editing involves genetic modifications to prevent, treat, or cure diseases such as sickle cell anemia and cystic fibrosis, with the aim of restoring normal health. It is generally considered ethically acceptable when safe and effective. In contrast, enhancement editing seeks to improve traits beyond normal health, such as intelligence, memory, athletic ability, or appearance. This raises concerns about unfair advantages, social inequality, discrimination, and genetic selection, making enhancement editing a highly controversial application of CRISPR technology.
Genetic Inequality
The benefits of CRISPR technology may not be equally accessible to everyone. Gene-editing treatments are often expensive and require advanced medical infrastructure, making them more available to wealthy individuals and developed countries. This creates the risk of genetic inequality, where some groups gain biological advantages while others are left behind.Such inequality raises important ethical concerns, including increased social divisions, unequal access to healthcare, the creation of genetically privileged groups, and discrimination based on genetic status. For example, if genetic enhancement becomes commercially available, wealthy families may be able to provide enhanced traits to their children, further widening existing social and economic inequalities.Therefore, many bioethicists argue that fairness and equal access must be carefully considered before allowing the widespread use of genetic enhancement technologies. This is essential to ensure that the benefits of CRISPR are shared equitably across society
Biosecurity and Bioterrorism
Biosecurity refers to measures aimed at preventing the misuse of biological research and biotechnology. Since CRISPR technology is relatively accessible and inexpensive, concerns exist about its misuse by individuals, organizations, or hostile groups. Potential risks include the creation of harmful pathogens, development of drug-resistant microorganisms, unauthorized genetic experimentation, and accidental release of modified organisms.Bioterrorism involves the deliberate use of biological agents to cause harm or disruption. Experts fear that gene-editing technologies could potentially be used to modify dangerous microorganisms. Although such risks remain largely hypothetical, they highlight the need for strong regulatory and ethical safeguards.
Balancing Innovation and Ethics
The ethical debate surrounding CRISPR technology is not about whether scientific progress should occur, but how it should occur responsibly. Ethical governance should ensure respect for human dignity, protection of future generations, fair access to benefits, prevention of discrimination, responsible scientific research, and strong oversight mechanisms. A balanced approach allows society to benefit from gene-editing technology while minimizing ethical risks. As gene-editing technology continues to evolve, ethical principles must guide its development to ensure that scientific progress respects human rights, promotes justice, and protects present and future generations.
INTERNATIONAL GUIDELINES AND LEGAL FRAMEWORK GOVERNING CRISPR TECHNOLOGY
The development of CRISPR-Cas9 technology has created major regulatory challenges worldwide. Since gene editing affects human health, genetic identity, and future generations, international organizations and governments have adopted legal and ethical frameworks to regulate its use. Although no universal treaty governs human gene editing, principles such as human dignity, safety, informed consent, and accountability guide existing regulations. The World Health Organization (WHO) issued recommendations on human genome editing in 2021, emphasizing protection of human rights, transparency in research, ethical review, public accountability, international cooperation, and caution regarding germline gene editing. Similarly, UNESCO’s Universal Declaration on the Human Genome and Human Rights (1997) recognizes the human genome as the heritage of humanity and stresses respect for human dignity, informed consent, and protection against genetic discrimination.In the United States, gene-editing activities are regulated by agencies such as the FDA and NIH. Human gene-therapy trials require approval, certain embryo-editing research faces funding restrictions, and germline editing for reproductive purposes is prohibited. Cases such as Moore v. Regents of the University of California (1990) highlighted issues of consent and commercialization of human biological materials. In the United Kingdom, the Human Fertilisation and Embryology Authority permits embryo gene editing only for licensed research, prohibits implantation of genetically modified embryos, and mandates strict ethical review. China strengthened its regulatory framework after the 2018 He Jiankui case involving genetically edited twins. Current regulations require ethical review, government approval for sensitive research, criminal penalties for violations, and increased monitoring of biotechnology research.
INDIA’S POSITION AND REGULATORY FRAMEWORK ON CRISPR TECHNOLOGY
CRISPR-Cas9 technology has created significant opportunities for genetic research, healthcare advancement, and biotechnology development in India. Its potential use in treating hereditary diseases and improving medical outcomes has attracted considerable scientific interest. However, because gene editing directly affects human life and may have consequences for future generations, India has adopted a cautious and regulated approach toward its application. India supports the use of CRISPR technology for research and therapeutic purposes under strict ethical supervision. The Government of India and scientific institutions encourage responsible innovation while ensuring that scientific progress is balanced with human dignity, public safety, and ethical responsibility. Human germline gene editing, particularly for reproductive purposes, is currently discouraged due to concerns regarding safety, long-term effects, and ethical implications.The Indian Council of Medical Research (ICMR) plays a central role in regulating biomedical and genetic research. Its ethical guidelines require informed consent, protection of privacy and confidentiality, ethical review, scientific validity, and protection of vulnerable groups. India does not have a specific law governing CRISPR technology and instead relies on the Environment (Protection) Act, 1986 and the Biosafety Rules, 1989. Regulatory bodies such as the Genetic Engineering Appraisal Committee (GEAC), Review Committee on Genetic Manipulation (RCGM), and Institutional Biosafety Committee (IBSC) oversee biotechnology research. Despite these safeguards, challenges remain, including regulatory gaps, genetic privacy concerns, ethical issues, and the absence of a clear framework for heritable gene editing.
CONCLUSION
CRISPR-Cas9 technology offers significant potential for treating genetic disorders and advancing medical research, but it also raises important legal and bioethical concerns, including informed consent, genetic privacy, human enhancement, germline editing, genetic inequality, and biosecurity. International organizations and several countries have adopted regulatory approaches emphasizing safety and ethical oversight. India has taken a cautious approach by permitting research under supervision while restricting clinical germline editing. However, existing biosafety regulations and ICMR guidelines are insufficient to address emerging challenges. Therefore, India requires a comprehensive legal framework that balances scientific innovation with ethical principles, human rights, privacy, and public welfare.
REFERENCES
BOOKS
1. Beyleveld, David & Shaun D. Pattinson, Medical Law and Ethics (4th edn., Sweet & Maxwell, London, 2019).
2. Green, Ronald M., Babies by Design: The Ethics of Genetic Choice (Yale University Press, New Haven, 2007).
3. Harris, John, Enhancing Evolution: The Ethical Case for Making Better People (Princeton University Press, New Jersey, 2007).
4. Laurie, Graeme, Genetic Privacy: A Challenge to Medico-Legal Norms (Cambridge University Press, Cambridge, 2002).
5. Rawls, John, A Theory of Justice (Revised edn., Harvard University Press, Massachusetts, 1999).
6. Robertson, John A., Children of Choice: Freedom and the New Reproductive Technologies (Princeton University Press, New Jersey, 1994).
7. Sandel, Michael J., The Case Against Perfection: Ethics in the Age of Genetic Engineering (Harvard University Press, Massachusetts, 2007).
8. Skloot, Rebecca, The Immortal Life of Henrietta Lacks (Crown Publishers, New York, 2010).
9. Sternberg, Samuel H. & Jennifer A. Doudna, A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution (Houghton Mifflin Harcourt, New York, 2017).
Journal articles
1. Doudna, Jennifer A. & Emmanuelle Charpentier, “The New Frontier of Genome Engineering with CRISPR-Cas9,” 346 Science 1258096 (2014).
2. Ishino, Yoshizumi et al., “Nucleotide Sequence of the iap Gene, Responsible for Alkaline Phosphatase Isozyme Conversion in Escherichia coli,” 169(12) Journal of Bacteriology 5429–5433 (1987).
3. “Birth of Gene-Edited Babies: A Case of Genome Editing in Humans,” 563 Nature 607–608 (2018).
4. “China Tightens Regulation of Human Genome Editing Following the Gene-Edited Babies Incident,” 577 Nature 154–155 (2020).
Cases
1. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1.
2. Moore v. Regents of the University of California, 793 P.2d 479 (Cal. 1990).
3. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1.
4. Suchita Srivastava v. Chandigarh Administration, (2009) 9 SCC 1.
Reports, guidelines and international instruments
1. Indian Council of Medical Research, National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017).
2. Indian Council of Medical Research, National Guidelines for Gene Therapy Product Development and Clinical Trials (2019).
3. National Academies of Sciences, Engineering, and Medicine, Biodefense in the Age of Synthetic Biology (National Academies Press, Washington D.C., 2018).
4. National Academies of Sciences, Engineering, and Medicine, Human Genome Editing: Science, Ethics, and Governance (National Academies Press, Washington D.C., 2017).
5. Nuffield Council on Bioethics, Genome Editing and Human Reproduction: Social and Ethical Issues (2018).
6. OECD, Guidelines on Human Biobanks and Genetic Research Databases (2009).
7. UNESCO, Universal Declaration on Bioethics and Human Rights (2005).
8. UNESCO, Universal Declaration on the Human Genome and Human Rights (1997).
9. World Health Organization, Human Genome Editing: Recommendations (WHO, Geneva, 2021).
Web sources
1. The Nobel Foundation, The Nobel Prize in Chemistry 2020 – Press Release, available at: https://www.nobelprize.org.
2. National Human Genome Research Institute, CRISPR-Cas9 Genome Editing, available at: https://www.genome.gov.
3. Broad Institute, CRISPR Technology Explained, available at: https://www.broadinstitute.org.
Statutes and rules
1. The Environment (Protection) Act, 1986.
2. Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or cells’ 1989